Literature DB >> 11783501

The role of deoxycytidine kinase in gemcitabine cytotoxicity.

C L van der Wilt1, J R Kroep, A M Bergman, W J Loves, E Alvarez, I Talianidis, S Eriksson, C J van Groeningen, H M Pinedo, G J Peters.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11783501     DOI： 10.1007/0-306-46843-3_56

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN： 0065-2598            Impact factor:   2.622


× No keyword cloud information.
  11 in total

1.  Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies.

Authors:  Soukaina Réjiba; Christelle Bigand; Céline Parmentier; Amor Hajri
Journal:  Neoplasia       Date:  2009-07       Impact factor: 5.715

2.  The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancer.

Authors:  Nadim Bou Zgheib; Yin Xiong; Douglas C Marchion; Elona Bicaku; Hye Sook Chon; Xiaomang Ba Stickles; Entidhar Al Sawah; Patricia L Judson; Ardeshir Hakam; Jesus Gonzalez-Bosquet; Robert M Wenham; Sachin M Apte; Christopher L Cubitt; Dung Tsa Chen; Johnathan M Lancaster
Journal:  Int J Oncol       Date:  2012-04-26       Impact factor: 5.650

3.  Phase II study of gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial.

Authors:  Sung Yong Oh; Won Seog Kim; Dae Ho Lee; Seok Jin Kim; Sung Hyun Kim; Baek Yeol Ryoo; Hye Jin Kang; Young Jin Choi; Joo Seop Chung; Hyo Jung Kim; Cheolwon Suh
Journal:  Invest New Drugs       Date:  2009-05-07       Impact factor: 3.850

4.  Synthesis and biological activity of a gemcitabine phosphoramidate prodrug.

Authors:  Weidong Wu; Jennifer Sigmond; Godefridus J Peters; Richard F Borch
Journal:  J Med Chem       Date:  2007-06-29       Impact factor: 7.446

5.  Novel strategy with gemcitabine for advanced pancreatic cancer.

Authors:  Shuji Komori; Shinji Osada; Kazuhiro Yoshida
Journal:  ISRN Oncol       Date:  2011-05-23

6.  Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells.

Authors:  Y Nakano; S Tanno; K Koizumi; T Nishikawa; K Nakamura; M Minoguchi; T Izawa; Y Mizukami; T Okumura; Y Kohgo
Journal:  Br J Cancer       Date:  2007-01-16       Impact factor: 7.640

7.  Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines.

Authors:  A M Bergman; H M Pinedo; I Talianidis; G Veerman; W J P Loves; C L van der Wilt; G J Peters
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

8.  Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene.

Authors:  Carlos María Galmarini; Marilyn L Clarke; Lars Jordheim; Cheryl L Santos; Emeline Cros; John R Mackey; Charles Dumontet
Journal:  BMC Pharmacol       Date:  2004-05-24

9.  Pegylated arginine deiminase synergistically increases the cytotoxicity of gemcitabine in human pancreatic cancer.

Authors:  Rouzbeh Daylami; Diego J Muilenburg; Subbulakshmi Virudachalam; Richard J Bold
Journal:  J Exp Clin Cancer Res       Date:  2014-12-12

10.  Molecular imaging of lymphoid organs and immune activation by positron emission tomography with a new [18F]-labeled 2'-deoxycytidine analog.

Authors:  Caius G Radu; Chengyi J Shu; Evan Nair-Gill; Stephanie M Shelly; Jorge R Barrio; Nagichettiar Satyamurthy; Michael E Phelps; Owen N Witte
Journal:  Nat Med       Date:  2008-06-08       Impact factor: 53.440
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.